Market Overview

UPDATE: Deutsche Bank Reiterates on Alexion Pharmaceuticals Ahead of Asfotase Alfa Launch

Share:
Related ALXN
Baird Says Alexion Pharmaceuticals Guidance Is Conservative
Earnings Scheduled For January 29, 2015
Alexion's Soliris' Label May be Updated upon EC Approval - Analyst Blog (Zacks)

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00.

In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe Hypophosphatasia (HPP). Our deep dive into the drug suggests the market is bigger vs. street expectations. We also updated our Soliris & expense assumptions to more accurately reflect company guidance. We believe incidence is greater than literature suggests & model 1/25,000 in US & 1/50,000 ex-US of severe pediatric HPP.”

Alexion Pharmaceuticals closed on Friday at $163.63.

Latest Ratings for ALXN

DateFirmActionFromTo
Jan 2015JefferiesMaintainsHold
Jan 2015CitigroupMaintainsNeutral
Jan 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALXN)

Around the Web, We're Loving...

Get Benzinga's Newsletters